SCHEMBL6347296

SCHEMBL6347296

CC(C)(C)OC(=O)N(CC(=O)N1CCC(Nc2cccnc2)CC1)c1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGLEC9 Q9Y336 2/20 0.49
EPHX2 P34913 1/20 0.44
GPR119 Q8TDV5 4/20 0.41
NOS2 P35228 1/20 0.41
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
USP30 Q70CQ3 2/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
GRIN2B Q13224 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6343306 0.89 SIGLEC9 (0.51) SIGLEC9EPHX2GPR119CCNA2CDK2
SCHEMBL6341787 0.82 SIGLEC9 (0.49) SIGLEC9EPHX2NOS2ALDH1A1MAPT
SCHEMBL6354873 0.79 EPHX2 (0.44) EPHX2GPR119USP30ALDH1A1MAPT
SCHEMBL6353754 0.78 ALDH1A1 (0.44) SIGLEC9EPHX2GPR119NOS2KEAP1
SCHEMBL6344507 0.78 EPHX2 (0.44) EPHX2GPR119
SCHEMBL6346955 0.78 NOS2 (0.54) GPR119NOS2USP30GRIN2B
SCHEMBL1876139 0.77 GPR119 (0.65) SIGLEC9EPHX2GPR119CCNA2CDK2
SCHEMBL31023936 0.77 GPR119 (0.65) SIGLEC9EPHX2GPR119CCNA2CDK2
Hydrochloric Acid SCHEMBL6344841 0.76 SIGLEC9 (0.42) SIGLEC9EPHX2CDK2MAPK1
SCHEMBL6343493 0.76 SIGLEC9 (0.46) SIGLEC9EPHX2NOS2CDK2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878725-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-04-12 US disclosed
US-20040242656-A1 Serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-12-02 US disclosed
EP-1289950-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2004-09-08 EP disclosed
US-20030078438-A1 Serine protease inhibitors ELI LILLY AND COMPANY 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078438-A1 Serine protease inhibitors HPN, LPXN, PRSS1 SIGLEC9 667/4885EPHX2 1259/4885GPR119 2924/4885
US-20040242656-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 SIGLEC9 925/4885EPHX2 1576/4885GPR119 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.